CollPlant Biotechnologies Ltd Ordinary Shares earnings per share and revenue
On 26 de nov. de 2025, CLGN reported earnings of -0.27 USD per share (EPS) for Q3 25, missing the estimate of 0.15 USD, resulting in a -270.78% surprise. Revenue reached 77.00 mil, compared to an expected 4.94 milhão, with a -98.44% difference. The market reacted with a -0.45% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.12 USD, with revenue projected to reach 1.55 milhão USD, implying an diminuir of -55.56% EPS, and aumentar of 1919.47% in Revenue from the last quarter.
FAQ
What were CollPlant Biotechnologies Ltd Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, CollPlant Biotechnologies Ltd Ordinary Shares reported EPS of -$0.27, missing estimates by -270.78%, and revenue of $77.00K, -98.44% below expectations.
How did the market react to CollPlant Biotechnologies Ltd Ordinary Shares's Q3 2025 earnings?
The stock price moved down -0.45%, changed from $2.24 before the earnings release to $2.23 the day after.
When is CollPlant Biotechnologies Ltd Ordinary Shares expected to report next?
The next earning report is scheduled for 24 de mar. de 2026.
What are the forecasts for CollPlant Biotechnologies Ltd Ordinary Shares's next earnings report?
Based on 4
analistas, CollPlant Biotechnologies Ltd Ordinary Shares is expected to report EPS of -$0.12 and revenue of $1.55M for Q4 2025.